Skip to main content
SpringerLink
Log in

Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer

  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A multicenter phase I pharmacokineticstudy of a new triphenylethylene antiestrogen, toremifene, was examined in 70 patients with advanced breast cancer. Patients were randomized to receive single daily oral doses of either 10, 20, 40, 60, 200, or 400 mg for 8 weeks. Plasma toremifene and its major metabolites,N-desmethyltoremifene and 4-hydroxytoremifene, were determined weekly during therapy and at 0, 7, 14, and 21 days after the discontinuation of therapy. The time to reach steady-state plasma concentrations was between 1 and 5 weeks, with steady-state being achieved earlier (1–2 weeks) at daily doses of 200 and 400 mg. The time to peak concentration following oral doses of toremifene ranged from 1.5 to 4.5 h. The terminal half-life of elimination was 5.0, 6.0, and 5.0 days for toremifene, desmethyltoremifene, and 4-hydroxytoremifene, respectively. Plasma concentrations of 4-hydroxytoremifene were detectable only at high doses (200 and 400 mg/day) of toremifene. The results of this phase I pharmacokinetic study show that toremifene has metabolic and kinetic patterns that are similar to those previously reported with tamoxifen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chiou WL (1978) Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of area under the plasma level time curve. J Pharmacokinet Biopharm 6: 539–546

    Google Scholar 

  2. Ebbs SR, Roberts JV, Baum M (1987) Alternative mechanism of action of “anti-oestrogens” in breast cancer. Lancet: (2) 621

  3. Fabian C, Sternson L, Barnett M (1980) Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 64: 765–773

    Google Scholar 

  4. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 409–417

    Google Scholar 

  5. Holleran WM, Gharbo SA, DeGregorio MW (1987) Quantitation of toremifene and its major metabolites in human plasma by high-performance liquid chromatography following fluorescent activation. Anal Lett 20 (6): 871–879

    Google Scholar 

  6. Horwitz KB, McGuire WL (1978) Nuclear mechanisms of estrogen action. Effects of estadiol and antiestrogens on estrogen receptors and nuclear receptor processing. J Biol Chem 253: 2185–2191

    Google Scholar 

  7. Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perila M, Pippo I, Sundquist H, Sodervall M, Toivola R (1986) A new triphenylethylene compound, Fc-1157a: hormonal effects. Cancer Chemother Pharmacol 17: 103–108

    Google Scholar 

  8. Kangas L, Nieminen AL, Blanco G, Gronroos M, Kallio S, Karjalainen A, Perila M, Sodervall M, Toivola R (1986) A new triphenylethylene compound, Fc-1157a: antitumor effects. Cancer Chemother Pharmacol 17: 109–113

    Google Scholar 

  9. Riegelman S, Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharm Sci 65: 509–535

    Google Scholar 

  10. Sutherland RL, Murphy LC, Hall RE, Reddel RR, Watts CK, Taylor IW (1984) Effects of antiestrogens on human breast cancer cells in vitro: interactions with high affinity intracellular binding sites and effects on cell proliferation kinetics. In: Bresciam F, Kinb RJB, Lippman ME, Namer M, Raynaud JP (Eds), Hormones and Cancer 2, Progress in Cancer Research and Therapy, vol XXXI. Raven Press, New York, pp 193–212

    Google Scholar 

  11. Watts CKW, Murphy LC, Sutherland RL (1987) Antioestrogen binding sites. In: Furr BJA, Wakeling AE (eds) Pharmacology and clinical uses of inhibitors of hormone secretion and action. Bailliere Tindall, London, pp 20–40

    Google Scholar 

  12. Wilson AJ, Baum M, Singh L, Kangas L (1987) Antioestrogen therapy of pure mesenchymal tumor. Lancet: 508

  13. Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, langrange, and spline approximation. J Pharmacokinet Biopharm 6: 79–98

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research Institute, University of California, San Francisco, CA

    Christopher C. Benz

  2. Adria Laboratories, Columbus, Ohio, USA

    Irving Shemano

  3. Section of Medical Oncology, Yale University, 333 Cedar Street, P. O. Box 3333, 06510, New Haven, CT, USA

    Valerie J. Wiebe, Timothy B. Cadman & Michael W. DeGregorio

Authors
  1. Valerie J. Wiebe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher C. Benz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irving Shemano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Timothy B. Cadman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael W. DeGregorio
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by a grant from Adria Laboratories

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiebe, V.J., Benz, C.C., Shemano, I. et al. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother. Pharmacol. 25, 247–251 (1990). https://doi.org/10.1007/BF00684880

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00684880

Keywords

Search

Navigation